Abstract: Phytonutrient based compositions and methods of using the same for preventing, reducing, or treating genetic damage induced by environmental toxins are disclosed.
Type:
Grant
Filed:
December 14, 2012
Date of Patent:
March 5, 2019
Assignee:
METAPROTEOMICS, LLC
Inventors:
Andrea Lyra Heller, Brian Carroll, Matthew L. Tripp, Jeffrey S. Bland
Abstract: Disclosed are compositions and methods comprising supplemented oils for improving health, reducing cardiovascular risk factors, or treating certain conditions.
Abstract: Methods and compositions that can be used to promote bone and joint health through amelioration, stabilization and repair of damage associated with various pathophysiological conditions are disclosed.
Type:
Grant
Filed:
March 14, 2008
Date of Patent:
August 26, 2014
Assignee:
Metaproteomics, LLC
Inventors:
Matthew L. Tripp, Veera Konda, Anu Desai, Amy J. Hall, Jeffrey S. Bland
Abstract: Disclosed is a pharmaceutical composition including a therapeutic quantity of a COX-2 inhibitor having an IC50-WHMA COX-2/COX-1 ratio ranging from about 0.23 to about 3.33 with reduced gastrointestinal and cardiovascular toxicity. Also disclosed are methods for treating osteoarthritis, rheumatoid arthritis or acute pain with less side-effects and faster onset of action utilizing the disclosed pharmaceutical composition.
Abstract: Phytonutrient based compositions and methods of using the same for preventing, reducing, or treating genetic damage induced by environmental toxins are disclosed. Additionally, said compositions and methods are used to reduce oxidized low density lipoproteins (OxLDL), myeloperoxidase (MPO), and plasminogen activator inhibitor-1 (PAI-1).
Type:
Application
Filed:
May 17, 2013
Publication date:
December 19, 2013
Applicant:
METAPROTEOMICS, LLC
Inventors:
Veera KONDA, Andrea Lyra HELLER, Anu DESAI, Brian CARROLL, Matthew L. TRIPP, Jeffrey S. BLAND
Abstract: Disclosed is a pharmaceutical composition including a therapeutic quantity of a COX-2 inhibitor having an IC50-WHMA COX-2/COX-1 ratio ranging from about 0.23 to about 3.33 with reduced gastrointestinal and cardiovascular toxicity. Also disclosed are methods for treating osteoarthritis, rheumatoid arthritis or acute pain with less side-effects and faster onset of action utilizing the disclosed pharmaceutical composition.
Abstract: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
Type:
Grant
Filed:
April 30, 2012
Date of Patent:
October 15, 2013
Assignee:
Metaproteomics, LLC
Inventors:
Matthew L. Tripp, John G. Babish, Jeffrey S. Bland, Gary K. Darland, Robert Lerman, Daniel O. Lukaczer, DeAnn J. Liska, Terrence Howell
Abstract: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
Type:
Grant
Filed:
October 20, 2003
Date of Patent:
July 16, 2013
Assignee:
Metaproteomics, LLC.
Inventors:
Matthew L. Tripp, John G. Babish, Jeffrey S. Bland, Gary Darland, Robert Lerman, Daniel O. Lukaczer, DeAnn J. Liska, Terrence Howell
Abstract: Compositions and methods for enhancing heavy metal detoxification are described. The compositions and methods described provide enhanced activity of key detoxification systems including that the induction of phase II detoxification enzymes, such as glutathione S-transferases (GSTs), and NADPH quinone reductase (NQO1) activity.
Type:
Grant
Filed:
January 18, 2012
Date of Patent:
July 2, 2013
Assignee:
Metaproteomics, LLC
Inventors:
Matthew L. Tripp, Veera Konda, Amy J. Hall, Anu Desai, Jeffrey S. Bland
Abstract: Phytonutrient based compositions and methods of using the same for preventing, reducing, or treating genetic damage induced by environmental toxins are disclosed.
Abstract: Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs.
Type:
Application
Filed:
June 1, 2012
Publication date:
March 14, 2013
Applicant:
Metaproteomics, LLC
Inventors:
Matthew L. Tripp, John G. Babish, Jeffrey S. Bland, Amy J. Hall, Veera Konda, Linda M. Pacioretty
Abstract: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
Type:
Application
Filed:
April 30, 2012
Publication date:
October 25, 2012
Applicant:
METAPROTEOMICS, LLC
Inventors:
Matthew L. Tripp, John G. Babish, Jeffrey S. Bland, Gary K. Darland, Robert Lerman, Daniel O. Lukaczer, DeAnn J. Liska, Terrence Howell
Abstract: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
Type:
Grant
Filed:
March 26, 2012
Date of Patent:
September 4, 2012
Assignee:
Metaproteomics, LLC
Inventors:
Matthew L. Tripp, John G. Babish, Jeffrey S. Bland, Gary K. Darland, Robert Lerman, Daniel O. Lukaczer, DeAnn J. Liska, Terrence M. Howell
Abstract: Compositions and methods for enhancing heavy metal detoxification are described. The compositions and methods described provide enhanced activity of key detoxification systems including that the induction of phase II detoxification enzymes, such as glutathione S-transferases (GSTs), and NADPH quinone reductase (NQO1) activity.
Type:
Grant
Filed:
February 13, 2008
Date of Patent:
August 14, 2012
Assignee:
Metaproteomics, LLC
Inventors:
Matthew L. Tripp, Veera Konda, Amy Hall, Anu Desai, Jeffrey S. Bland
Abstract: Compositions and methods for enhancing heavy metal detoxification are described. The compositions and methods described provide enhanced activity of key detoxification systems including that the induction of phase II detoxification enzymes, such as glutathione S-transferases (GSTs), and NADPH quinone reductase (NQO1) activity.
Type:
Application
Filed:
January 18, 2012
Publication date:
July 26, 2012
Applicant:
Metaproteomics, LLC
Inventors:
Matthew L. Tripp, Veera Konda, Amy Hall, Anu Desai, Jeffrey S. Bland
Abstract: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
Type:
Application
Filed:
March 26, 2012
Publication date:
July 19, 2012
Applicant:
METAPROTEOMICS, LLC
Inventors:
Matthew L. Tripp, John G. Babish, Jeffrey S. Bland, Gary K. Darland, Robert Lerman, Daniel O. Lukaczer, DeAnn J. Liska, Terrence Howell
Abstract: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
Type:
Application
Filed:
March 26, 2012
Publication date:
July 12, 2012
Applicant:
METAPROTEOMICS, LLC
Inventors:
Matthew L. Tripp, John G. Babish, Jeffrey S. Bland, Gary K. Darland, Robert Lerman, Daniel O. Lukaczer, DeAnn J. Liska, Terrence Howell
Abstract: Disclosed are botanically based compositions and methods useful for the treatment of metabolic syndrome and diabetes type 2. Compositions, kits, and methods are additionally disclosed for means to augment the activity of identified glucose and insulin regulating drugs.
Type:
Grant
Filed:
December 7, 2006
Date of Patent:
June 26, 2012
Assignee:
Metaproteomics, LLC
Inventors:
Matthew L. Tripp, John G. Babish, Jeffrey S. Bland, Amy J. Hall, Veera Konda, Linda M. Pacioretty
Abstract: The invention provides compositions containing a fraction isolated or derived from hops and a methylxanthine. The invention additionally provides compositions containing a fraction derived from hops and a curcuminoid. The invention also provides methods of using such compositions to reduce inflammation.
Type:
Grant
Filed:
March 28, 2011
Date of Patent:
June 5, 2012
Assignee:
Metaproteomics, LLC
Inventors:
John G. Babish, Matthew L. Tripp, Jeffrey S. Bland
Abstract: A natural formulation of compounds that would to modulate inflammation is disclosed. The formulation would also inhibit expression of COX-2, inhibit synthesis of prostaglandins selectively in target cells, and inhibit inflammatory response selectively in target cells. The compositions containing at least one fraction isolated or derived from hops. Other embodiments relate to combinations of components, including at least one fraction isolated or derived from hops, tryptanthrin and conjugates thereof, rosemary, an extract or compound derived from rosemary, a triterpene species, or a diterpene lactone or derivatives or conjugates thereof.
Type:
Grant
Filed:
March 29, 2007
Date of Patent:
May 1, 2012
Assignee:
Metaproteomics, LLC
Inventors:
Matthew L. Tripp, John G. Babish, Jeffrey S. Bland, Gary K. Darland, Robert Lerman, Daniel O. Lukaczer, DeAnn J. Liska, Terrence Howell